SynAct Pharma AB (publ) SYNACT.ST
Nasdaq Tukholma · Terveydenhuolto · Biotechnology
Pidä tämä osake seurantalistallasi ja aseta sähköposti-ilmoitukset kursseista, raporteista ja tärkeistä tiedotteista, kun niitä on saatavilla.
Terveydenhuolto, Nasdaq Tukholma
126 osaketta toimialalla. SynAct Pharma on sijalla 95/115.
Toimialan järjestys vertaa osakkeita vain keskenään: kunkin osakkeen laatu-, arvo- ja momentumpisteet muutetaan sen sijaksi toimialan osakkeiden joukossa välillä 0 (heikoin) – 100 (paras), ja järjestys perustuu niiden keskiarvoon. Kirjaudu lisätäksesi nousuvaran tavoitehintaan järjestykseen.
Laatu ja arvo
Ylöspäin on korkeampi laatu, oikealle halvempi. Kuplan koko on markkina-arvo.
Toimialan järjestys
Osien keskiarvo, 0–100.
Kaikki toimialan osakkeet
| # | Yhtiö | Toimialapisteet | Laatu | Arvo | Momentum | Nousuvara tavoitehintaan | P/E | ROE | Osinkotuotto | 1 vuosi | Ohjeistus saavutettu | Markkina-arvo (milj.) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sprint Bioscience SPRINT.ST | 93 | 94 | 64 | 84 | 🔒 | 4,3 | 77,0% | 0,0% | +417,9% | – | 397 |
| 2 | Xbrane Biopharma XBRANE.ST | 91 | 94 | 73 | 72 | 🔒 | 2,0 | 22,7% | 0,0% | +24,4% | – | 257 |
| 3 | Nolato NOLA-B.ST | 80 | 71 | 62 | 61 | 🔒 | 18,0 | 14,1% | 3,3% | −10,2% | – | 14 008 |
| 4 | Attendo ATT.ST | 79 | 54 | 52 | 93 | 🔒 | 23,6 | 14,9% | 1,4% | +67,8% | – | 19 178 |
| 5 | Ambea AMBEA.ST | 78 | 51 | 51 | 94 | 🔒 | 24,1 | 12,8% | 1,4% | +60,0% | – | 16 034 |
| 6 | Arjo ARJO-B.ST | 76 | 46 | 61 | 80 | 🔒 | 29,7 | 4,5% | 2,6% | +22,2% | – | 9 903 |
| 7 | Synsam SYNSAM.ST | 76 | 66 | 62 | 57 | 🔒 | 18,7 | 18,6% | 3,0% | −1,8% | – | 8 469 |
| 8 | CellaVision CEVI.ST | 76 | 84 | 35 | 86 | 🔒 | 31,6 | 17,2% | 1,4% | +29,7% | – | 4 842 |
| 9 | Saniona SANION.ST | 76 | 95 | 66 | 20 | 🔒 | 5,8 | 44,8% | 0,0% | −23,7% | – | 1 656 |
| 10 | Arcoma ARCOMA.ST | 75 | 70 | 53 | 65 | 🔒 | 24,2 | 6,7% | 0,0% | +13,6% | – | 122 |
| 11 | Getinge GETI-B.ST | 75 | 59 | 46 | 86 | 🔒 | 32,7 | 7,7% | 1,8% | +27,3% | – | 73 867 |
| 12 | AstraZeneca AZN.ST | 72 | 75 | 39 | 73 | 🔒 | 28,1 | 21,0% | 1,7% | +14,6% | – | 2 850 298 |
| 13 | Elekta EKTA-B.ST | 71 | 31 | 47 | 87 | 🔒 | – | −7,3% | 3,9% | +44,6% | – | 23 746 |
| 14 | BioGaia BIOG-B.ST | 71 | 90 | 32 | 76 | 🔒 | 37,5 | 25,3% | 3,2% | +30,5% | – | 12 473 |
| 15 | Cantargia CANTA.ST | 69 | 94 | 72 | 8 | 🔒 | 2,5 | 55,3% | 0,0% | −51,8% | – | 366 |
| 16 | BioArctic BIOA-B.ST | 68 | 91 | 32 | 63 | 🔒 | 26,9 | 52,0% | 0,6% | +15,0% | – | 27 532 |
| 17 | RaySearch Laboratories RAY-B.ST | 68 | 82 | 48 | 43 | 🔒 | 25,9 | 23,1% | 2,3% | −16,6% | – | 5 897 |
| 18 | Perpetua Medical PERP-B.ST | 68 | 81 | 80 | 9 | 🔒 | 3,1 | 12,4% | 0,0% | −65,9% | – | 8 |
| 19 | Orexo ORX.ST | 67 | 100 | 77 | 2 | 🔒 | 0,1 | 130,3% | 0,0% | −95,9% | – | 37 |
| 20 | Surgical Science Sweden SUS.ST | 67 | 70 | 42 | 55 | 🔒 | 46,2 | 1,6% | 0,0% | −26,3% | – | 3 090 |
| 21 | Mendus IMMU.ST | 66 | – | 60 | 38 | 🔒 | – | −19,4% | 0,0% | −19,8% | – | 305 |
| 22 | AddLife ALIF-B.ST | 66 | 56 | 36 | 74 | 🔒 | 39,6 | 10,3% | 0,8% | −1,0% | – | 22 179 |
| 23 | BICO Group BICO.ST | 66 | 14 | 51 | 86 | 🔒 | – | −62,3% | 0,0% | +16,1% | – | 1 743 |
| 24 | Stille STIL.ST | 64 | 69 | 26 | 81 | 🔒 | 41,1 | 7,9% | 0,0% | +45,9% | – | 2 287 |
| 25 | Medicover MCOV-B.ST | 64 | 53 | 34 | 80 | 🔒 | 46,8 | 14,5% | 0,9% | +12,6% | – | 40 085 |
| 26 | Apotea APOTEA.ST | 64 | 69 | 25 | 84 | 🔒 | 48,4 | 27,1% | 0,6% | +19,8% | – | 11 063 |
| 27 | Carasent CARA.ST | 64 | 71 | 29 | 66 | 🔒 | 50,7 | 4,3% | 0,0% | −6,2% | – | 1 756 |
| 28 | Vimian Group VIMIAN.ST | 63 | 56 | 24 | 89 | 🔒 | 63,8 | 4,5% | 0,0% | +42,5% | – | 22 051 |
| 29 | BrainCool BRAIN.ST | 63 | 19 | 37 | 93 | 🔒 | – | −21,1% | 0,0% | +87,6% | – | 430 |
| 30 | Moberg Pharma MOB.ST | 63 | 23 | 56 | 60 | 🔒 | – | −4,1% | 0,0% | −4,0% | – | 478 |
| 31 | Camurus CAMX.ST | 62 | 90 | 14 | 85 | 🔒 | 58,3 | 17,4% | 0,0% | +30,4% | – | 42 917 |
| 32 | Bonesupport Holding BONEX.ST | 62 | 84 | 10 | 86 | 🔒 | 145,7 | 16,4% | 0,0% | +62,2% | – | 20 706 |
| 33 | Sectra SECT-B.ST | 61 | 90 | 20 | 79 | 🔒 | 109,7 | 26,4% | 0,7% | +10,6% | – | 61 846 |
| 34 | Isofol Medical ISOFOL.ST | 61 | – | 28 | 84 | 🔒 | – | −50,2% | 0,0% | +112,3% | – | 414 |
| 35 | IDL Diagnostics IDLDX.ST | 61 | 28 | 60 | 37 | 🔒 | – | −8,2% | 0,0% | −17,5% | – | 73 |
| 36 | Alvotech ALVO-SDB.ST | 61 | 40 | 37 | 69 | 🔒 | 52,6 | – | 0,0% | −4,0% | – | 14 556 |
| 37 | Scandinavian Real Heart AB (Publ) HEART.ST | 60 | – | 46 | 51 | 🔒 | – | −56,8% | 0,0% | +3,9% | – | 80 |
| 38 | MedCap MCAP.ST | 60 | 75 | 24 | 68 | 🔒 | 37,6 | 15,1% | 0,0% | +1,2% | – | 8 268 |
| 39 | Sedana Medical SEDANA.ST | 59 | 28 | 49 | 52 | 🔒 | – | −6,6% | 0,0% | −2,1% | – | 956 |
| 40 | Genovis AB (publ.) GENO.ST | 58 | 81 | 16 | 81 | 🔒 | 66,8 | 8,6% | 0,0% | +7,7% | – | 1 569 |
| 41 | Vivesto VIVE.ST | 58 | – | 63 | 16 | 🔒 | – | −27,4% | 0,0% | −63,3% | – | 45 |
| 42 | Vitrolife VITR.ST | 57 | 12 | 57 | 56 | 🔒 | – | −63,5% | 0,9% | −15,4% | – | 16 010 |
| 43 | Bactiguard Holding BACTI-B.ST | 55 | 33 | 38 | 52 | 🔒 | – | −2,5% | 0,0% | −8,5% | – | 545 |
| 44 | Integrum INTEG-B.ST | 55 | 20 | 46 | 52 | 🔒 | – | −26,9% | 0,0% | −0,7% | – | 216 |
| 45 | Flerie FLERIE.ST | 54 | – | 63 | 11 | 🔒 | – | −22,4% | 0,0% | −61,9% | – | 1 151 |
| 46 | Swedish Orphan Biovitrum SOBI.ST | 54 | 49 | 21 | 83 | 🔒 | 347,3 | 1,3% | 0,0% | +45,9% | – | 165 986 |
| 47 | Paxman PAX.ST | 54 | 54 | 22 | 75 | 🔒 | – | −4,1% | 0,0% | −3,1% | – | 1 443 |
| 48 | Boule Diagnostics BOUL.ST | 54 | 31 | 70 | 6 | 🔒 | – | −2,2% | 0,0% | −80,2% | – | 49 |
| 49 | Dynavox Group DYVOX.ST | 53 | 68 | 28 | 42 | 🔒 | 46,0 | 27,5% | 0,7% | −22,3% | – | 7 616 |
| 50 | Nanexa NANEXA.ST | 53 | 50 | 12 | 86 | 🔒 | – | −11,2% | 0,0% | +474,0% | – | 1 590 |
| 51 | C-Rad CRAD-B.ST | 52 | 66 | 34 | 28 | 🔒 | 72,4 | 3,0% | 0,4% | −30,3% | – | 757 |
| 52 | Asker Healthcare Group ASKER.ST | 52 | 46 | 30 | 47 | 🔒 | 57,1 | 7,5% | 0,5% | −19,2% | – | 28 096 |
| 53 | Alzinova ALZ.ST | 51 | – | 64 | 7 | 🔒 | – | −21,5% | 0,0% | −74,8% | – | 35 |
| 54 | Physitrack PTRK.ST | 51 | 12 | 43 | 56 | 🔒 | – | −87,2% | 0,0% | −23,4% | – | 184 |
| 55 | SenzaGen SENZA.ST | 51 | 26 | 42 | 37 | 🔒 | – | −14,9% | 0,0% | −20,6% | – | 140 |
| 56 | Mentice MNTC.ST | 51 | 49 | 24 | 63 | 🔒 | – | −23,4% | 0,0% | +22,3% | – | 378 |
| 57 | ScandiDos SDOS.ST | 51 | 31 | 58 | 12 | 🔒 | – | −8,2% | 0,0% | −57,3% | – | 26 |
| 58 | Iconovo ICO.ST | 50 | 10 | 61 | 30 | 🔒 | – | −36,8% | 0,0% | −39,5% | – | 56 |
| 59 | Intervacc IVACC.ST | 50 | 14 | 51 | 32 | 🔒 | – | −29,4% | 0,0% | −19,2% | – | 264 |
| 60 | SpectraCure SPEC.ST | 49 | – | 66 | 2 | 🔒 | – | −59,9% | 0,0% | −92,0% | – | 8 |
| 61 | Neola Medical NEOLA.ST | 49 | – | 60 | 9 | 🔒 | – | −14,5% | 0,0% | −64,4% | – | 40 |
| 62 | Ortoma ORT-B.ST | 48 | 25 | 34 | 45 | 🔒 | – | −13,5% | 0,0% | −35,2% | – | 395 |
| 63 | BioInvent International BINV.ST | 47 | 12 | 63 | 10 | 🔒 | – | −59,7% | 0,0% | −90,4% | – | 201 |
| 64 | Infant Bacterial Therapeutics IBT-B.ST | 46 | – | 20 | 76 | 🔒 | – | −61,9% | 0,0% | +18,8% | – | 962 |
| 65 | AlzeCure Pharma ALZCUR.ST | 46 | – | 17 | 82 | 🔒 | – | −144,8% | 0,0% | +216,7% | – | 848 |
| 66 | Xvivo Perfusion XVIVO.ST | 46 | 62 | 18 | 47 | 🔒 | 255,4 | 1,2% | 0,0% | +17,5% | – | 6 426 |
| 67 | Xspray Pharma XSPRAY.ST | 45 | – | 52 | 12 | 🔒 | – | −28,3% | 0,0% | −48,5% | – | 558 |
| 68 | Fluicell FLUI.ST | 45 | 11 | 30 | 63 | 🔒 | – | −76,4% | 0,0% | +118,3% | – | 38 |
| 69 | NextCell Pharma NXTCL.ST | 45 | 8 | 59 | 26 | 🔒 | – | −77,8% | 0,0% | −69,8% | – | 29 |
| 70 | Cinclus Pharma Holding CINPHA.ST | 45 | 12 | 43 | 32 | 🔒 | – | −49,8% | 0,0% | −30,4% | – | 566 |
| 71 | Enzymatica ENZY.ST | 44 | 15 | 25 | 56 | 🔒 | – | −41,8% | 0,0% | +20,3% | – | 590 |
| 72 | Modus Therapeutics Holding MODTX.ST | 44 | – | 39 | 26 | 🔒 | – | −204,4% | 0,0% | −56,3% | – | 19 |
| 73 | Promimic PRO.ST | 43 | 26 | 35 | 22 | 🔒 | – | −14,8% | 0,0% | −40,2% | – | 159 |
| 74 | OssDsign OSSD.ST | 43 | 24 | 46 | 13 | 🔒 | – | −16,4% | 0,0% | −65,3% | – | 413 |
| 75 | Nosa Plugs NOSA.ST | 42 | 23 | 34 | 27 | 🔒 | – | −19,6% | 0,0% | −36,3% | – | 113 |
| 76 | Senzime SEZI.ST | 42 | 14 | 41 | 25 | 🔒 | – | −45,1% | 0,0% | −36,0% | – | 555 |
| 77 | Ascelia Pharma ACE.ST | 42 | – | 57 | 3 | 🔒 | – | −76,7% | 0,0% | −82,0% | – | 68 |
| 78 | Magle Chemoswed Holding MAGLE.ST | 42 | 11 | 66 | 1 | 🔒 | – | −84,0% | 0,0% | −97,9% | – | 8 |
| 79 | Active Biotech ACTI.ST | 42 | – | 43 | 15 | 🔒 | – | −67,1% | 0,0% | −46,2% | – | 91 |
| 80 | Q-linea QLINEA.ST | 42 | 9 | 55 | 18 | 🔒 | – | −54,0% | 0,0% | −43,9% | – | 264 |
| 81 | S2Medical S2M.ST | 42 | 11 | 62 | 7 | 🔒 | – | −102,2% | 0,0% | −70,4% | – | 4 |
| 82 | Egetis Therapeutics EGTX.ST | 41 | 6 | 18 | 96 | 🔒 | – | −101,2% | 0,0% | +72,4% | – | 4 386 |
| 83 | Devyser Diagnostics DVYSR.ST | 40 | 52 | 24 | 21 | 🔒 | – | −2,4% | 0,0% | −44,4% | – | 1 066 |
| 84 | Vicore Pharma Holding VICO.ST | 40 | 9 | 34 | 50 | 🔒 | – | −43,6% | 0,0% | +4,0% | – | 3 091 |
| 85 | Initiator Pharma INIT.ST | 39 | – | 28 | 35 | 🔒 | – | −46,3% | 0,0% | −15,6% | – | 170 |
| 86 | Corline Biomedical CLBIO.ST | 39 | 18 | 30 | 28 | 🔒 | – | −15,7% | 0,0% | −31,6% | – | 330 |
| 87 | Ortivus ORTI-B.ST | 39 | 15 | 27 | 37 | 🔒 | – | −97,6% | 0,0% | −11,1% | – | 93 |
| 88 | Episurf Medical EPIS-B.ST | 39 | 6 | 38 | 45 | 🔒 | – | −122,5% | 0,0% | +104,0% | – | 103 |
| 89 | Biovica International BIOVIC-B.ST | 39 | 8 | 49 | 21 | 🔒 | – | −80,9% | 0,0% | −47,5% | – | 90 |
| 90 | AcouSort ACOU.ST | 38 | 10 | 28 | 47 | 🔒 | – | −74,6% | 0,0% | +10,3% | – | 63 |
| 91 | EQL Pharma EQL.ST | 37 | 40 | 26 | 13 | 🔒 | 60,9 | 4,7% | 0,0% | −52,6% | – | 763 |
| 92 | Clinical Laserthermia Systems CLS-B.ST | 36 | 11 | 54 | 5 | 🔒 | – | −59,7% | 0,0% | −80,4% | – | 56 |
| 93 | Medivir MVIR.ST | 36 | 8 | 29 | 46 | 🔒 | – | −60,8% | 0,0% | +180,4% | – | 591 |
| 94 | Spago Nanomedical SPAGO.ST | 36 | 5 | 51 | 20 | 🔒 | – | −86,4% | 0,0% | −65,1% | – | 29 |
| 95 | SynAct Pharma SYNACT.ST | 36 | – | 25 | 33 | 🔒 | – | −65,1% | 0,0% | −29,5% | – | 814 |
| 96 | ExpreS2ion Biotech Holding EXPRS2.ST | 36 | 5 | 64 | 2 | 🔒 | – | −106,7% | 0,0% | −94,3% | – | 9 |
| 97 | IRLAB Therapeutics IRLAB-A.ST | 35 | 5 | 22 | 71 | 🔒 | – | −358,1% | 0,0% | −4,5% | – | 195 |
| 98 | Immunovia IMMNOV.ST | 33 | 1 | 64 | 3 | 🔒 | – | −225,3% | 0,0% | −90,0% | – | 21 |
| 99 | Cereno Scientific CRNO-B.ST | 33 | – | 39 | 7 | 🔒 | – | −46,6% | 0,0% | −78,0% | – | 507 |
| 100 | Annexin Pharmaceuticals ANNX.ST | 32 | – | 35 | 10 | 🔒 | – | −148,0% | 0,0% | −65,8% | – | 65 |
| 101 | Nanologica NICA.ST | 32 | 5 | 57 | 3 | 🔒 | – | −226,5% | 0,0% | −86,5% | – | 15 |
| 102 | Ortivus ORTI-A.ST | 31 | 15 | 21 | 29 | 🔒 | – | −97,6% | 0,0% | −27,5% | – | 159 |
| 103 | FluoGuide FLUO.ST | 30 | – | 23 | 29 | 🔒 | – | −72,4% | 0,0% | −29,2% | – | 481 |
| 104 | Pila Pharma PILA.ST | 30 | 5 | 26 | 45 | 🔒 | – | −116,1% | 0,0% | −29,6% | – | 67 |
| 105 | Prostatype Genomics PROGEN.ST | 29 | 2 | 58 | 2 | 🔒 | – | −167,8% | 0,0% | −81,5% | – | 15 |
| 106 | Dicot Pharma DICOT.ST | 23 | – | 22 | 20 | 🔒 | – | −109,4% | 0,0% | −49,6% | – | 497 |
| 107 | Alligator Bioscience ATORX.ST | 22 | 1 | 49 | 0 | 🔒 | – | −748,7% | 0,0% | −99,5% | – | 7 |
| 108 | Elicera Therapeutics ELIC.ST | 22 | – | 24 | 14 | 🔒 | – | −74,5% | 0,0% | −54,2% | – | 129 |
| 109 | Acarix ACARIX.ST | 20 | 5 | 25 | 20 | 🔒 | – | −126,0% | 0,0% | −40,4% | – | 189 |
| 110 | OncoZenge ONCOZ.ST | 19 | 4 | 25 | 18 | 🔒 | – | −188,0% | 0,0% | −34,6% | – | 42 |
| 111 | Gabather GABA.ST | 18 | – | 18 | 15 | 🔒 | – | −702,7% | 0,0% | −45,4% | – | 8 |
| 112 | Neem's Hill NEEMS-B.ST | 17 | 9 | 17 | 13 | 🔒 | – | −252,9% | 0,0% | −60,9% | – | 54 |
| 113 | iZafe Group IZAFE-B.ST | 15 | 6 | 22 | 9 | 🔒 | – | −142,7% | 0,0% | −71,1% | – | 75 |
| 114 | Luxbright LXB.ST | 12 | 10 | 16 | 2 | 🔒 | – | −72,4% | 0,0% | −90,6% | – | 825 |
| 115 | SciBase Holding SCIB.ST | 11 | 5 | 20 | 9 | 🔒 | – | −1 307,8% | 0,0% | −53,8% | – | 59 |
| – | Hansa Biopharma HNSA.ST | – | – | – | 76 | 🔒 | – | – | 0,0% | +37,7% | – | 3 884 |
| – | Oncopeptides ONCO.ST | – | – | – | 27 | 🔒 | – | – | 0,0% | −62,5% | – | 491 |
| – | Klaria Pharma Holding AB (publ.) KLAR.ST | – | – | – | 31 | 🔒 | – | – | 0,0% | +3,2% | – | 128 |
| – | Xintela XINT.ST | – | – | – | 12 | 🔒 | – | – | 0,0% | −63,9% | – | 121 |
| – | Simris Group AB (PUBL) SIMRIS-B.ST | – | – | – | 55 | 🔒 | – | – | 0,0% | +3,7% | – | 86 |
| – | Enorama Pharma ERMA.ST | – | – | – | 35 | 🔒 | – | – | 0,0% | −73,4% | – | 55 |
| – | Disruptive Pharma DPHA.ST | – | – | – | – | 🔒 | – | – | 0,0% | – | – | 44 |
| – | Aino Health AINO.ST | – | – | – | 62 | 🔒 | – | – | 0,0% | −20,4% | – | 41 |
| – | Qlife Holding QLIFE.ST | – | – | – | 13 | 🔒 | – | – | 0,0% | −55,7% | – | 15 |
| – | Diamyd Medical DMYD-B.ST | – | – | – | 2 | 🔒 | – | −60,6% | 0,0% | −90,6% | – | – |
| – | Newbury Pharmaceuticals NEWBRY.ST | – | – | – | 59 | 🔒 | – | – | 0,0% | −1,0% | – | – |
Lajittele napsauttamalla otsikkoa. Markkina-arvo miljoonina (SEK). Ei sijoitusneuvontaa. Vertaa osakekursseja →
Ei sijoitusneuvontaa. Luvuissa voi olla tietolähteen virheitä.